<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
INDP
Indaptus Therapeutics
$
()


  • Indaptus Therapeutics announces interim data from Phase 1 INDP-D101 trial

    11/6/2023 - 08:13am
  • Indaptus to present interim data of first cohort in trial of INDP-D101

    10/31/2023 - 09:12am
  • Indaptus Therapeutics doses first patient in second cohort of study of Decoy20

    9/19/2023 - 08:03am
  • Indaptus Therapeutics reports Q2 EPS (39c) vs (46c) last year

    8/14/2023 - 08:02am
  • Indaptus Therapeutics announces opening of next cohort in trial of Decoy20

    8/10/2023 - 08:46am
  • Indaptus Therapeutics appoints Waltzman as Chief Medical Officer

    8/7/2023 - 08:09am
  • Indaptus Therapeutics expects cash to fund operations into 2Q24

    5/11/2023 - 07:06am
  • Indaptus Therapeutics reports Q1 EPS (51c) vs. (41c) last year

    5/11/2023 - 07:05am
  • Indaptus receives notice of allowance from IP India for Decoy platform

    5/9/2023 - 08:25am
  • Indaptus Therapeutics presents data on preclinical efficacy of Decoy

    4/19/2023 - 08:10am
  • Indaptus Therapeutics receives Brazilian patent allowance for Decoy platform

    4/17/2023 - 08:15am
  • Indaptus Therapeutics price target lowered to $12 from $15 at H.C. Wainwright

    3/20/2023 - 06:16am
  • Indaptus Therapeutics reports 2022 EPS ($1.73) vs ($1.89) last year

    3/17/2023 - 08:07am
  • Indaptus Therapeutics activates Emory Winship Cancer Institute as trial site

    3/13/2023 - 08:41am
  • Indaptus Therapeutics doses first subject in ongoing Phase 1 lab

    3/7/2023 - 08:27am
dynamic_feed Breaking News